Physician profile
Stephen Bendheim
NPI 1194793356
$2,312.25
in general payments reported to CMS, 2019-2025
28 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $204 · 2021: $386 · 2022: $566 · 2023: $305 · 2024: $262 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671 · Education: $77.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.43 |
| Education | $77.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.61 | 2021-2025 | Wegovy |
| Abbvie INC. | $414.06 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Exeltis, USA INC. | $226.57 | 2019-2025 | Slynd |
| Lilly USA, LLC | $165.49 | 2024-2025 | Zepbound |
| Pfizer INC. | $122.06 | 2019-2024 | |
| Astellas Pharma US INC | $101.53 | 2019-2024 | Veozah |
| Mayne Pharma Commercial LLC | $94.43 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.58 | 2021-2024 | |
| Avion Pharmaceuticals | $71.16 | 2019 | |
| Therapeuticsmd, INC. | $65.42 | 2019-2020 | |
| Millicent US INC | $60.57 | 2025 | Femring, Intrarosa |
| Optumhealth Care Solutions, LLC | $51.55 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
| Amag Pharmaceuticals, INC. | $42.38 | 2019-2020 | |
| Organon LLC | $38.36 | 2021-2024 | |
| Daiichi Sankyo INC. | $37.02 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $33.57 | 2019-2021 | |
| Lupin INC. | $33.06 | 2020-2021 | |
| Amgen INC. | $28.50 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $27.38 | 2021-2022 | |
| Allergan, INC. | $25.85 | 2019-2020 | |
| Kvk-Tech, INC. | $23.64 | 2024 | |
| Sumitomo Pharma America, INC. | $18.77 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $18.21 | 2023 | Vivjoa |
| Scynexis, INC. | $18.19 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.51 | 2019 | |
| Coopersurgical, INC. | $15.03 | 2024 | Paragard T 380a |
| Biogen, INC. | $15.00 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bendheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.